Maximizing productivity in biopharmaceutical research and clinical development

The cost and effort of bringing biopharmaceutical drugs to market has escalated dramatically. The pharma industry is therefore continually looking for new ways to identify safer, more efficacious drug candidates earlier, with less effort and cost, and advance them onto the market. Explore three case studies that demonstrate how Gyrolab^® systems contribute to achieving this overall goal, accelerating and improving the process of launching more efficacious biopharmaceutical drugs onto the market. The case studies examine a range of areas, including preclinical pharmacokinetic (PK) studies; preclinical nephrotoxicity assessment; and the transition from Phase I to Phase II/III clinical trials.